In addition, further investigations exploring the genotype–phenotype correlations of specific BRCA1 and BRCA2 mutations that differentiate prognosis among family members who are carriers of the same mutations are needed to clarify the role of other genetic abnormalities and co-contributing risk factors in the clinical course of BRCA-mutated ovarian cancer patients. This evidence concerns the gene BRCA1 and ovarian carcinoma.